These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 13246056)

  • 1. [Studies and research on Mycobacteria. XIV. PAS metabolism in various PAS-resistant Mycobacteria].
    PENSO G; CATTANEO C; MORELLINI M; VICARI G
    Rend Ist Sup Sanit; 1955; 18(1-2):17-24. PubMed ID: 13246056
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of antituberculous drugs upon the oxygen consumption of mycobacteria.
    SUZUKI T
    Sci Rep Res Inst Tohoku Univ Med; 1955 Jan; 6(1):89-95. PubMed ID: 13246659
    [No Abstract]   [Full Text] [Related]  

  • 3. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.
    Rengarajan J; Sassetti CM; Naroditskaya V; Sloutsky A; Bloom BR; Rubin EJ
    Mol Microbiol; 2004 Jul; 53(1):275-82. PubMed ID: 15225321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the drug resistance in mycobacteria with genetic reference; on the frequency of appearance of PAS-resistant mutants in Mycobacterium tuberculosis var. hominis simultaneously resistant to streptomycin and isoniazid.
    TSUKAMURA M
    J Antibiot (Tokyo); 1956 Sep; 9(5):186-90. PubMed ID: 13385196
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of PAS on metabolism in Mycobacterium tuberculosis].
    WESTFAL I
    Med Dosw Mikrobiol; 1952; 4(3):405-6. PubMed ID: 13002061
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012.
    Zhang X; Liu L; Zhang Y; Dai G; Huang H; Jin Q
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1320-4. PubMed ID: 25421465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Problem of hormesis induced by synthetic antituberculosis agents].
    POLSTER M
    G Ital Chemioter; 1956; 3(1-2):33-6. PubMed ID: 13365993
    [No Abstract]   [Full Text] [Related]  

  • 8. [The resistance of Mycobacterium tuberculosis to PAS].
    GIUNIO N
    Tuberkuloza; 1954; 6(2-3):135-41. PubMed ID: 13226448
    [No Abstract]   [Full Text] [Related]  

  • 9. Some observations on the composition of bacterial population of PAS-resistant Mycobacterium tuberculosis.
    TSUKAMURA M
    Am Rev Tuberc; 1958 Feb; 77(2):346-9. PubMed ID: 13509033
    [No Abstract]   [Full Text] [Related]  

  • 10. The bactericidal activities of combinations of streptomycin, isoniazid, p-aminosalicylic acid (PAS), oxytetracycline (terramycin) and viomycin against Mycobacterium tuberculosis.
    SINGH B; MITCHISON DA
    J Gen Microbiol; 1955 Aug; 13(1):176-84. PubMed ID: 13252227
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of combined treatment with streptomycin, PAS and isoniazid on resistance of Mycobacterium tuberculosis to streptomycin and isoniazid].
    JANKOV M
    Hig Cas Hig Mikrobiol Epidemiol Sanit Teh; 1955; 7(1-4):228-34. PubMed ID: 13405406
    [No Abstract]   [Full Text] [Related]  

  • 12. [Practical viewpoints of resistance against streptomycin, PAS, conteben].
    UNHOLTZ K
    Tuberkulosearzt; 1952 Aug; 6(8):451-9. PubMed ID: 13005732
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. tuberculosis].
    Zhang ZD; Zhao YL; Li ZH; Jia HY; Liu YH; Chen X; Liu ZQ; Du BP; Xing AY; Ma Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Sep; 30(9):683-5. PubMed ID: 18070553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biological effects of new PAS derivatives on Mycobacterium tuberculosis].
    Ertan M; Saygun N; Ureten M
    Mikrobiyol Bul; 1985 Jul; 19(3):121-6. PubMed ID: 3929034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certain saprophytic mycobacteria from soil sources forming a red color product from PAS.
    TSUKAMURA M
    Am Rev Respir Dis; 1961 Dec; 84():916. PubMed ID: 13922904
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical significance of resistant Mycobacterium tuberculosis.
    BLAHA H
    Med Klin; 1954 Aug; 49(34):1337-8. PubMed ID: 13203012
    [No Abstract]   [Full Text] [Related]  

  • 17. Formation of a red color product from PAS by certain mycobacteria.
    TSUKAMURA M
    Jpn J Tuberc; 1961 Dec; 9():70-9. PubMed ID: 13922908
    [No Abstract]   [Full Text] [Related]  

  • 18. Examinations of the effect of PAS on the prothrombin time.
    BRIX H
    Acta Tuberc Scand; 1955; 31(3-4):236-40. PubMed ID: 13326605
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of results after administration of drugs in the presence of Mycobacterium tuberculosis resistant].
    VICENTE-MASTELLARI A; YOUNG RV
    Arch Med Panamenos; 1956; 5(1):1-7. PubMed ID: 13341547
    [No Abstract]   [Full Text] [Related]  

  • 20. Knocking out salicylate biosynthesis genes in Mycobacterium smegmatis induces hypersensitivity to p-aminosalicylate (PAS).
    Nagachar N; Ratledge C
    FEMS Microbiol Lett; 2010 Oct; 311(2):193-9. PubMed ID: 20735479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.